Recent progress in antitumoral synthetic vaccines

ACS Medicinal Chemistry Letters

Volumn 5, Issue 11, 2014, Pages 1176-1178

  Nativi, Cristina ^a   Renaudet, Olivier ^b,c  

^a UNIVERSITY OF FLORENCE   (Italy)

^b UNIV GRENOBLE ALPES   (France)

^c INSTITUT UNIVERSITAIRE DE FRANCE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; CARBOHYDRATE ANTIGEN; CARBOHYDRATE DERIVATIVE; EPITOPE; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; KEYHOLE LIMPET HEMOCYANIN; MUCIN 1; QS 21; TOLL LIKE RECEPTOR 2;

ANTIGEN STRUCTURE; B LYMPHOCYTE; CANCER IMMUNOTHERAPY; CROSS PRESENTATION; CYTOTOXIC T LYMPHOCYTE; HUMAN; IMMUNE RESPONSE; PRIORITY JOURNAL; REVIEW;

EID: 84927587090     PISSN: None     EISSN: 19485875     Source Type: Journal    
DOI: 10.1021/ml5003794     Document Type: Review

References (12)

1. Wilson, R. M.; Danishefsky, S. J. A vision for vaccines built from fully synthetic tumor-associated antigens: from the laboratory to the clinic J. Am. Chem. Soc. 2013, 135, 14462-14472
2. Miles, D.; Roché, H.; Martin, M.; Perren, T. J.; Cameron, D. A.; Glaspy, J.; Dodwell, D.; Parker, J.; Mayordomo, J.; Tres, A.; Murray, J. L.; Ibrahim, N. K. The Theratope Study Group. Phase III multicenter clinical trial of the sialyl-Tn (STn)-keyhole limpet hemocyanin (KLH) vaccine for metastatic breast cancer Oncologist 2011, 16, 1092-1100
3. Zhu, J.; Wan, Q.; Lee, D.; Yang, G.; Spassova, M. K.; Ouerfelli, O.; Ragupathi, G.; Damani, P.; Livingston, P. O.; Danishefsky, S. J. From synthesis to biologics: preclinical data on a chemistry derived anticancer vaccine J. Am. Chem. Soc. 2009, 131, 9298-9303
4. Cai, H.; Huang, Z.-H.; Shi, L.; Sun, Z.-Y.; Zhao, Y.-F.; Kunz, H.; Li, Y.-M. Variation of the glycosylation pattern in MUC1 glycopeptide BSA vaccines and its influence on the immune response Angew. Chem., Int. Ed. 2012, 51, 1719-1723
5. Ingale, S.; Wolfert, M. A.; Buskas, T.; Boons, G. J. Increasing the antigenicity of synthetic tumor-associated carbohydrate antigens by targeting toll-like receptors ChemBioChem 2009, 10, 455-463
6. Wilkinson, B. L.; Day, S.; Malins, L. R.; Apostolopoulos, V.; Payne, R. J. Self-adjuvating multicomponent cancer vaccine candidates combining per-glycosylated MUC1 glycopeptides and the Toll-like receptor 2 agonist Pam3CysSer. Angew. Chem., Int. Ed. 2011, 50, 1635-1639
7. Renaudet, O.; Dasgupta, G.; Bettahi, I.; Shi, A.; Nesburn, A. B.; Dumy, P.; BenMohamed, L. Linear and branched glyco-lipopeptides vaccines follow distinct cross-presentation pathways and generate different magnitudes of antitumor immunity PLoS One 2010, 5, e11216
8. Lakshminarayanan, V.; Thompson, P.; Wolfert, M. A.; Buskas, T.; Bradley, J. M.; Pathangey, L. B.; Madsen, C. S.; Cohen, P. A.; Gendler, S. J.; Boons, G.-J. Immune recognition of tumor-associated mucin MUC1 is achieved by a fully synthetic aberrantly glycosylated MUC1 tripartite vaccine Proc. Natl. Acad. Sci. U.S.A. 2012, 109, 261-266
9. Cai, H.; Sun, Z.-Y.; Chen, M.-S.; Zhao, Y.-F.; Kunz, H.; Li, Y.-M. Synthetic multivalent glycopeptide-lipopeptide antitumor vaccines: Impact of the cluster effect on the killing of tumor cells Angew. Chem., Int. Ed. 2014, 53, 1699-1703
10. Cai, H.; Chen, M.-S.; Sun, Z.-Y.; Zhao, Y.-F.; Kunz, H.; Li, Y.-M. Self-adjuvating synthetic antitumor vaccines from MUC1 glycopeptides conjugated to T-cell epitopes from tetanus toxoid Angew. Chem., Int. Ed. 2013, 52, 6106-6110
11. Hoffmann-Röder, A.; Kaiser, A.; Wagner, S.; Gaidzik, N.; Kowalczyk, D.; Westerlind, U.; Gerlitzki, B.; Schitt, E.; Kunz, H. Synthetic antitumor vaccines from tetanus toxoid conjugates of MUC1 glycopeptides with the Thomsen-Friedenreich antigen and a fluorine-substituted analogue Angew. Chem., Int. Ed. 2010, 49, 8498-8503
12. Richichi, B.; Thomas, B.; Fiore, M.; Bosco, R.; Qureshi, H.; Nativi, C.; Renaudet, O.; BenMohamed, L. A cancer therapeutic vaccine based on clustered Tn-antigen mimetics induces strong antibody-mediated protective immunity Angew. Chem., Int. Ed. 2014, 10.1002/anie.201406897